KR20180099529A - Pharmaceutical composition containing rosae laevigatae with anti-allergy or anti-inflammatory activity and preparation method for the same - Google Patents

Abstract

The present invention discloses a pharmaceutical composition for anti-inflammation and anti-allergy and a method for manufacturing the same. The pharmaceutical composition for anti-inflammation and anti-allergy according to an embodiment of the present invention comprises: 1-30 parts by weight of Rosa laevigata; 1-30 parts by weight of Brewey′s yeast; 1-30 parts by weight of Chaenomeles sinensis; 1-30 parts by weight of grape stems; 1-30 parts by weight of reed; 1-20 parts by weight of green tea; 1-20 parts by weight of Prunus tomentosa; 1-20 parts by weight of Acanthopanax sessiliflorum; and 1-10 parts by weight of pine pollen. The pharmaceutical composition of the present invention is free from cytotoxicity and has few side effects, and thus can be used as safe medicines and health functional foods.

Description

FIELD OF THE INVENTION [0001] The present invention relates to a pharmaceutical composition for anti-inflammatory and antiallergic medicaments, and to a method for producing the same, and a method for producing the same. BACKGROUND ART < RTI ID = 0.0 >

The present invention relates to a pharmaceutical composition for antiinflammatory and antiallergic treatment and a method for preparing the same. More particularly, the present invention relates to a pharmaceutical composition for anti-inflammatory and antiallergic drugs having an anti-allergic effect against? -Hexosaminidase And to a process for preparing the same.

As our society has rapidly changed into a modern society, our lifestyles have changed, and our urban life patterns are fast and busy, lacking 24 hours. On the other hand, the liver has time to recharge when it is fasting or sleeping, and these modern habits also affect the activation of advanced secondary functions in addition to detoxification. Hormonal metabolism, etc., are also more active when the digestive system is free of food, physical activity is minimized, or sleep is sufficiently long. Moreover, workers who suffer from heavy work and stress, frequent night shifts, and groups that are having frequent meetings are likely to be exposed to physical imbalance risks due to minority or midnight snacks.

The liver plays an important role in detoxifying all foods that are absorbed by the body, storing nutrients in the liver, and being secreted like bile to regulate blood flow. If the liver function is low, GOT, GPT, GTP (Gamma jittii) will rise, and waste products and toxins will not be discharged well. Various complications (hepatic coma, ascites, esophageal varices, thrombocytopenia) Abdominal bloating (etc.) Headache, gum bleeding occurs. The liver is called the organ of silence, so self-diagnosis is not easy.

On the market, medicines, beverages, and health functional foods with liver function are on the market, but they focus on enzymes that directly function in relation to drinking and liver function. Sleep and liver function are closely linked, and inflammation is a biological reaction caused by such an imbalance. Detoxification and new cell formation to enhance the quality of sleep and to activate the advanced functions of the liver, thereby providing a composition that has both sleeping function and liver function at the same time, and can further inhibit the inflammatory response The need for natural medicines using herbal medicines is emerging.

Inflammation is the defense of biological tissues against injury to the body. That is, in response to various harmful stressors, the biological defense reaction to recover the original state by removing the injury caused by stimulation is an inflammatory reaction. Irritation of inflammation includes infection, chemical, and physical stimulation. Biocomponents related to the inflammatory reaction include low-molecular or high-molecular chemicals such as free radicals, proteins, saccharides and lipids, plasma, blood cells, blood vessels and connective tissues.

The process of inflammation is usually divided into two categories, acute inflammation and chronic inflammation can be divided into. Acute inflammation is a short-term reaction within a few days. Plasma components and blood cells are involved in the removal of foreign matter by displaying the circulatory system. Chronic inflammation has a long duration and involves tissue proliferation.

Most allergic diseases are caused by chemical agents (mainly histamine, prostaglandins, leukotrienes, TNFa, cytokines, etc.) liberated from the granules of mast cells of tissues activated by antigen-antibody reaction ), Etc.). Because the use of currently used allergenic drugs remains symptom-relieving, the development of more fundamental therapeutic drugs is urgently required.

The key mediators that induce inflammatory and allergic diseases are prostaglandins, leukotriens, platelet activating factor (PAF), phospholipase A2, cyclooxygenase ) And arachidonic acid, which is a precursor by lipoxygenase. Enzymes related to nitric oxide synthase (NOS) biosynthesis, an enzyme that generates nitric oxide (NO), are also known to play an important role in mediating inflammatory responses.

Thus, NOS, an enzyme that produces NO from L-arginine, is also a major target in blocking inflammation. Recent studies have shown that there are several types of NOS, including brain nOS (brain NOS), nNOS (neuronal NOS) in the brain, and endothelial NOS (eNOS) , And the small amount of NO produced by them plays an important role in maintenance of normal body homeostasis such as induction of neurotransmission and vasodilation. In contrast, various inflammatory cytokines or lipopoly- NO is induced by iNOS (induced NOS) induced by external stimuli such as ssacharide, LPS, etc., is known to cause cytotoxicity or various inflammatory responses, and chronic inflammation is associated with an increase in iNOS activity (Miller MJ et al., Mediators of inflammation, 4, pp387-396, 1995: Appleton L. et al., Adv. Pharmacol., 35, pp27-28, 1996).

In order to treat the above-mentioned inflammatory diseases, various kinds of inflammatory disease therapeutic agents have been developed. The therapeutic agents for inflammatory diseases reported so far are induced by acute inflammation in damaged tissue cells, cells involved in inflammation or chemotactic factors Is a drug that inhibits the production of eicosanoids from the cell membrane of leukocytes.

In addition, drugs that inhibit degranulation, inhibition of histamine receptors, inhibition of leukotriene generation, and blockade of leukotriene receptors are inhibited in the allergic antigen-antibody reaction.

These drugs are susceptible to steroid hazards during chronic use, and addictive and addictive disadvantages are pointed out. Due to the adverse effects on the nature of medicines, there is a need for a natural therapeutic composition.

Korean Patent No. 10-1743617, "Pharmaceutical Composition for the Treatment of Inflammatory Diseases Containing Extract Extracts" Korean Patent No. 10-1687770, " Pharmaceutical composition and food composition of anti-inflammatory antioxidant activity containing extract of Yangju jujube extract " Korean Patent Publication No. 10-2017-0015956, "Pharmaceutical composition for preventing and treating allergic diseases or contact dermatitis containing cymbidium extract as an active ingredient"

It is an object of embodiments of the present invention to provide a pharmaceutical composition for anti-inflammation and antiallergic having an anti-allergic effect against? -Hexosaminidase including gold.

The pharmaceutical composition for anti-inflammatory and antiallergic according to one embodiment of the present invention comprises 1 to 30 parts by weight of gold scales, 1 to 30 parts by weight of brewer's yeast, 1 to 30 parts by weight of scarlet wood, 1 to 30 parts by weight of grape stem, 1 to 30 parts by weight of reed, 1 to 20 parts by weight of green tea, 1 to 20 parts by weight of cherry wood, 1 to 20 parts by weight of acacia wood and 1 to 10 parts by weight of pine mushroom.

The pharmaceutical composition may further comprise 20 to 50 parts by weight of honey.

The pharmaceutical composition may comprise at least one of a pharmaceutically acceptable carrier, excipient and diluent.

The pharmaceutical composition can inhibit the secretion of? -Hexosaminidase.

The method for preparing a pharmaceutical composition for anti-inflammation and antiallergic according to an embodiment of the present invention comprises 1 to 30 parts by weight of a gold scab, 1 to 30 parts by weight of brewer's yeast, 1 to 30 parts by weight of scarlet, 1 to 30 1 to 30 parts by weight of reed, 1 to 20 parts by weight of green tea, 1 to 20 parts by weight of cherry wood, 1 to 20 parts by weight of oak tree and 1 to 10 parts by weight of pine powder are dried, ; Aging the mixed medicament at a temperature of 40 캜 to 65 캜 for 4 hours to 10 hours; Formulating the aged medicament into a ring form having a size of 3 mm to 5 mm; And drying the ring at a temperature of 30 ° C to 45 ° C for 2 hours to 5 hours.

Adding 1 to 50 parts by weight of honey to the mixed medicament and mixing the mixture.

The pharmaceutical composition may comprise at least one of a pharmaceutically acceptable carrier, excipient and diluent.

According to embodiments of the present invention, the pharmaceutical composition for anti-inflammatory and anti-allergy may have an anti-allergic effect on? -Hexosaminidase by including gold.

According to the embodiments of the present invention, the pharmaceutical composition for anti-inflammation and anti-allergy inhibits secretion of allergen-inducing substances from mast cells at a low concentration by containing gold, By inhibiting or blocking secretion of allergen-inducing substances in cells, it is possible to treat allergic diseases fundamentally.

In addition, according to the embodiments of the present invention, the pharmaceutical composition for anti-inflammation and anti-allergy has no cytotoxicity, and has few side effects, so that it can be useful as safe medicines and health functional foods.

Hereinafter, embodiments of the present invention will be described in detail with reference to the accompanying drawings and accompanying drawings, but the present invention is not limited to or limited by the embodiments.

The terminology used herein is for the purpose of illustrating embodiments and is not intended to be limiting of the invention. In the present specification, the singular form includes plural forms unless otherwise specified in the specification. It is noted that the terms "comprises" and / or "comprising" used in the specification are intended to be inclusive in a manner similar to the components, steps, operations, and / Or additions.

As used herein, the terms "embodiment," "example," "side," "example," and the like should be construed as advantageous or advantageous over any other aspect or design It does not.

Also, the term 'or' implies an inclusive or 'inclusive' rather than an exclusive or 'exclusive'. That is, unless expressly stated otherwise or clear from the context, the expression 'x uses a or b' means any of the natural inclusive permutations.

Also, the phrase "a" or "an ", as used in the specification and claims, unless the context clearly dictates otherwise, or to the singular form, .

The terms used in the following description are chosen to be generic and universal in the art to which they are related, but other terms may exist depending on the development and / or change in technology, customs, preferences of the technician, and the like. Accordingly, the terminology used in the following description should not be construed as limiting the technical thought, but should be understood in the exemplary language used to describe the embodiments.

Also, in certain cases, there may be a term chosen arbitrarily by the applicant, in which case the detailed description of the meaning will be given in the corresponding description section. Therefore, the term used in the following description should be understood based on the meaning of the term, not the name of a simple term, and the contents throughout the specification.

On the other hand, the terms first, second, etc. may be used to describe various elements, but the elements are not limited by terms. Terms are used only for the purpose of distinguishing one component from another.

It will also be understood that when an element such as a film, layer, region, configuration request, etc. is referred to as being "on" or "on" another element, And the like are included.

Unless defined otherwise, all terms (including technical and scientific terms) used herein may be used in a sense commonly understood by one of ordinary skill in the art to which this invention belongs. Also, commonly used predefined terms are not ideally or excessively interpreted unless explicitly defined otherwise.

In the following description of the present invention, a detailed description of known functions and configurations incorporated herein will be omitted when it may make the subject matter of the present invention rather unclear. The terminology used herein is a term used for appropriately expressing an embodiment of the present invention, which may vary depending on the user, the intent of the operator, or the practice of the field to which the present invention belongs. Therefore, the definitions of these terms should be based on the contents throughout this specification.

The present invention provides a pharmaceutical composition for antiinflammation and antiallergic treatment, comprising a progeny as an active ingredient.

The pharmaceutical composition for anti-inflammation and antiallergic according to the embodiment of the present invention comprises 1 to 30 parts by weight of gold scales, 1 to 30 parts by weight of brewer's yeast, 1 to 30 parts by weight of scarlet, 1 to 30 parts by weight of grape stem, 1 to 30 parts by weight of green tea, 1 to 20 parts by weight of green tea, 1 to 20 parts by weight of cherry wood, 1 to 20 parts by weight of an acacia tree and 1 to 10 parts by weight of pine powder.

There is no particular limitation on the morphology of the gold progenitor, beer yeast, quince tree, grape stem, reed, green tea, cherry tree, acacia tree, and sesame oil contained in the pharmaceutical composition for anti-inflammation and antiallergic according to the embodiment of the present invention, The powder may be contained in the pharmaceutical composition as a powder after drying, or may be contained in the pharmaceutical composition as an extract.

In the extract, the extraction method is not particularly limited, and extraction can be carried out according to a method commonly used in the art. Examples of the extraction method include, but are not limited to, hydrothermal extraction, ultrasonic extraction, filtration, and reflux extraction. These may be carried out singly or in combination with two or more methods. Preferably, Can be performed.

The kind of the extraction solvent used for the extraction is not particularly limited, and any solvent known in the art can be used. Nonlimiting examples of the extraction solvent include water, distilled water, methanol, ethanol, propanol, isopropanol, butanol, acetone, ether, benzene, chloroform, ethyl acetate, methylene chloride, n-hexane, hydrochloric acid, acetic acid, formic acid, Cyclohexane, and the like. When an alcohol is used as a solvent, C1 to C4 alcohols (methanol, ethanol, propanol, butanol) can be preferably used. More preferably, water, ethanol or a mixture thereof can be used as an extraction solvent.

When the amount of the pigment is less than 1 part by weight, the content of the indicator substance is insufficient. When the amount of the pigment is more than 30 parts by weight, there is a problem.

ROSAE LAEVIGATAE refers to the fruit of the Rosa laevigata Michaux. It is also known as Zaiza, free-spirits, mountain stones, .

Origin is growing in mountains, fields and gravel, which are devastated by China, Japan, and Taiwan. The height of the herb is 5m, the stem is reddish brown and there is a thorn like a hook. . Flowers bloom in June to July at the end of small branches. The fruit is elliptical, with thorns and ripen in yellow.

For medicinal purposes, roots, leaves, flowers, and berries are used; for food, berries, petals, and young lilies are used. Citrus acid, malic acid, tannin, resin, vitamin C, saponin, fructose, sucrose, starch, ), And the fruit is known to have the effects of anti-inflammatory, anti-allergic, tonic, gangjeong, convergence, antibacterial and cholesterol lowering effects. It is used for the treatment of enteritis, fever, uterine bleeding and the like.

In addition, it is not only effective in the treatment of nocturnal enuresis, but also effective in regulating women's illness or poor circulation, and also has the effect of stopping diarrhea.

The progenitor used in the pharmaceutical composition according to one embodiment of the present invention may be at least one selected from the group consisting of roots, leaves, flowers and fruits.

The brewer's yeast contains 1 part by weight to 30 parts by weight per 100 parts by weight of the total amount of the pharmaceutical composition. If the brewer's yeast is less than 1 part by weight, quantitative analysis of the active substance is impossible. If the brewer's yeast exceeds 30 parts by weight, There is a problem in the formulation according to the present invention.

Brewer's yeast is responsible for fermenting beer. When beer is separated from the beer making process, the beer is opened on the top and brewer's yeast is submerged on the bottom. It is prepared by instant drying at 150 to 200 ° C, (Brewey's Yeast). Brewer's yeast has been used for a long time for the purpose of medical treatment and health promotion, and has recently been attracting attention as a high-protein food that activates brain cells by scholars.

Brewer's yeast can be obtained by fermenting beer with Saccharomyces cerevisiae using a strain and drying the remaining cells.

If the amount of the quince tree is less than 1 part by weight, quantitative analysis of the active substance is impossible. If the quince tree exceeds 30 parts by weight, color There is a problem in the formulation depending on the concentration of the compound.

The quince may include a stem, a fruit, a leaf or a mixture thereof, and may preferably be a quince tree trunk.

The antiallergic effect of quercetin exhibits an inhibitory effect on secretion of allergen - inducing substances, an inhibitory effect on cytokine production, and an inhibitory effect on various signal transduction pathways that cause allergic induction.

The fruit of the present invention exhibits an anti-allergic effect at low concentrations and an anti-allergic effect at an excessively high concentration of about 80% or more. In addition, it is possible to inhibit the production of tumor necrosis factor-α (TNF-α) and interleukin-6 (IL-6), which are well known as cytokines, in a significant and concentration-dependent manner, Among the various signaling pathways, extracellular signal-regulated kinases (ERK), p38 mitogen-activated protein kinase (MAPK) and c-jun N-terminal kinase (JNK) - Dependable can be suppressed.

In addition, the quince has a variety of pharmacological effects such as promoting digestion, blood and hematopoiesis, antidiuretic action, and releasing the muscles of the stomach and limb, and having power, and at the same time, has activity to restrain fatigue and stress.

The grape stalk includes 1 to 30 parts by weight per 100 parts by weight of the total pharmaceutical composition. When the grape stalk is less than 1 part by weight, there is a problem that quantitative analysis of the effective substance is impossible. When the grape stalk exceeds 30 parts by weight, There is a problem with the formulation.

The grape is a stem belonging to the Vitaceae, and its generic name is Vitidis Viniferae Caulis, which may include both grape fruit and vine, and may particularly include the stem of a vine.

Ingredients include minerals such as calcium, phosphorus, iron, sodium, and magnesium. Especially, it is good for restoring fatigue because of a lot of sugar and it is rich in vitamins, so it can smooth metabolism. Its efficacy has blood, hematopoiesis, and antiviral effects, and it also contains anti-cancer components such as resveratrol.

Reeds contain 1 to 30 parts by weight per 100 parts by weight of the total amount of the pharmaceutical composition. If the reeds are less than 1 part by weight, quantitative analysis is impossible. If the reeds are more than 30 parts by weight, .

The reeds are preferably roots, and the reed roots are also called roots. It has pharmacological action, diuretic action, antipyretic action, liver protective action and hematopoietic function strengthening action, as well as fatigue recovery and stress suppressing activity.

The green tea contains 1 to 20 parts by weight per 100 parts by weight of the total pharmaceutical composition. When the amount of the green tea is less than 1 part by weight, quantitative analysis is impossible. When the amount of the green tea is more than 20 parts by weight, .

Green tea has been extensively used as a health drink in the private sector and has been widely used by many scholars at home and abroad for the prevention of hypertension and arteriosclerosis, anticancer, antioxidative, diabetic, detoxifying, , And tooth decay prevention effect. The green tea leaves have 70 to 80 parts by weight of water and the remainder are solids such as polyphenols, caffeine, amino acids, carbohydrates, pigment components (chlorophyll, carotenoids, flavonol derivatives and anthocyanins), organic acids, , And inorganic components.

When the cherry is less than 1 part by weight, quantitative analysis is not possible. If the cherry is more than 20 parts by weight, it is difficult to formulate due to the concentration of color. .

Cherry tree is cherry tree, and cherry tree is ripe in June with its fruit, and taste sweet and sour. The nature is warm, flavorful and not toxic. Cho Jung-ik's rain (调 中 益脾) and makes the face shine.

When the amount of the acacia tree is less than 1 part by weight, quantitative analysis is impossible. When the acacia tree is more than 20 parts by weight, the concentration of color There is a problem with the formulation.

Ogaki is a deciduous broad-leaved shrub belonging to Araliaceae such as ginseng. It is also known as Ogapi and is produced in Korea, China and Russia. According to Dong-bo-bo-gang or Bon-gae Gangmok, it has been used for a long time and it is called 'second ginseng' by long-lasting taking the roots, stem and branches of the gangs.

When the amount of the pellets is less than 1 part by weight, there is a problem that quantitative analysis is impossible. If the pellet fraction exceeds 10 parts by weight, there is a problem in formulation due to the concentration of color .

Songhwa (pine flower) is a pollen of pine trees. It is characterized by a light yellow color and a sweet smell. The properties are warm, tasty, and not toxic. You can relax the five o'clock, remove the heat, heal all the pangs, pangs, and openings and remove the scam.

In addition, the pharmaceutical composition for anti-inflammation and antiallergic according to the embodiment of the present invention may further comprise 1 part by weight to 50 parts by weight of honey per 100 parts by weight of the pharmaceutical composition, and when the amount of honey is less than 1 part by weight There is a problem that quantitative analysis is impossible, and when the honey is more than 50 parts by weight, there is a problem in formulation due to the concentration of color.

Honey is a honey bee collecting natural honey and sap such as honey and stored in a honeycomb. The quality of honey varies depending on the type of honey, the taste, the season, The major component of honey is sugar, more than 60%, moisture is about 20%, and other nutrients are proteins, acids, and minerals.

Honey has been used for natural sweeteners and medicines for a long time and many researches are being carried out to utilize it as a raw material for cosmetics and pharmaceuticals as well as to be used as an additive to confectionery, fruits and drinks. The sugar content of honey is a monosaccharide, which is known to be valuable as a functional material because it contains a variety of physiological activity-related substances related to melanin production inhibitory activity, antimicrobial activity, anticancer activity, and antioxidation. have.

In addition, the pharmaceutical composition for anti-inflammation and anti-allergy according to an embodiment of the present invention may include at least one of pharmaceutically acceptable carrier, excipient and diluent.

The carrier, excipient or diluent may be selected from the group consisting of lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acicia gum, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methylcellulose, At least one member selected from the group consisting of polyvinylpyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil, dextrin, calcium carbonate, propylene glycol, liquid paraffin and physiological saline But it is not limited thereto, and any conventional carrier, excipient or diluent may be used.

In addition, the pharmaceutical composition for anti-inflammation and anti-allergy according to the embodiment of the present invention may further contain, in addition to the active ingredient, a nutrient, a vitamin, an electrolyte, a flavoring agent, a colorant, a thickening agent, a pectic acid and its salt, , Protective colloid thickening agents, pH adjusting agents, stabilizers, preservatives, glycerin, alcohols, carbonating agents used in carbonated drinks, and the like.

In addition, the pharmaceutical composition for anti-inflammation and antiallergic according to the embodiment of the present invention can be used for screening gold scales, honey, beer yeast, quercus, grape stem, reed, green tea, cherry, As a result of the anti-inflammatory and anti-allergy tests, the pharmaceutical compositions for anti-inflammation and anti-allergy according to the examples of the present invention were able to excellently alleviate inflammation and allergy symptoms.

"Mast cell" is a widely distributed cell, such as connective tissue of vertebrate animal, which contains histamine, serotonin, heparin,? -Hexosaminidase, β-HEX) and leukotrienes are contained in the form of granules. When cell collapse releases granules in cells, hypersensitivity (inflammation) occurs in tissues against them. These cells are known to act on blood clotting inhibition, permeability of blood vessels, and blood pressure.

In particular, the pharmaceutical composition for anti-inflammation and anti-allergy according to the embodiment of the present invention can inhibit the secretion of? -Hexosaminidase.

In particular, beta -hexosaminidase is a substance expressed in association with inflammation and allergic reactions and is involved in hydrolyzing N-acetyl-D-hexosamine of N-acetyl- beta -D-hexosaminidase Lt; / RTI > β-hexosaminidase may be a degranulation marker of immune cells, eg, mast cells, and substances that inhibit the secretion, expression or activity of β-hexosaminidase may be used in the treatment of inflammatory or allergic diseases .

However, the pharmaceutical composition for anti-inflammation and antiallergic according to the embodiment of the present invention inhibits the expression or activity of interleukin-4 (IL-4), inhibits degranulation of mast cells, enhances skin barrier function , And / or the expression or activity of regulated on activation (normal T cell expressed and secreted: RANTES) and macrophage-derived chemokine (MDC).

In addition, inhibition of degranulation of mast cells by a pharmaceutical composition for anti-inflammation and antiallergic according to an embodiment of the present invention may be one which reduces the secretion, expression or activity of? -Hexosaminidase. In addition, the enhancement of skin barrier function by a pharmaceutical composition for anti-inflammation and antiallergic according to an embodiment of the present invention may increase the expression or activity of SPINK5, increase the expression or activity of caspase-14, and / or increase KLK7 Lt; RTI ID = 0.0 > activity. ≪ / RTI >

In addition, a pharmaceutical composition for the treatment of inflammatory diseases and allergic diseases or a health functional food can be prepared by a pharmaceutical composition for anti-inflammation and antiallergic according to an embodiment of the present invention.

The food composition for improving inflammation and allergic diseases or the health functional food includes forms such as tablets, capsules, pills or liquids, and the food to which the composition of the present invention can be added includes, for example, , Beverages, gums, tea, vitamin complexes, and health functional foods.

Inflammatory diseases are selected from the group consisting of allergic diseases, inflammatory bowel disease, atherosclerosis, inflammatory collagen vascular disease, glomerulonephritis, inflammatory skin disease, sarcoidosis, retinitis, gastritis, hepatitis, enteritis, arthritis, tonsillitis, sore throat, bronchitis, pneumonia, pancreatitis, sepsis And nephritis.

The method for preparing a pharmaceutical composition for anti-inflammation and antiallergic according to an embodiment of the present invention comprises 1 to 30 parts by weight of a gold scab, 1 to 30 parts by weight of brewer's yeast, 1 to 30 parts by weight of scarlet, 1 to 30 1 to 30 parts by weight of reed, 1 to 20 parts by weight of green tea, 1 to 20 parts by weight of cherry wood, 1 to 20 parts by weight of oak tree and 1 to 10 parts by weight of pine powder are dried, ; Aging the mixed medicament at a temperature of 40 캜 to 65 캜 for 4 hours to 10 hours; Formulating the aged medicament into a ring form having a size of 3 mm to 5 mm; And drying the ring at a temperature of 30 ° C to 45 ° C for 2 hours to 5 hours.

The method for preparing a pharmaceutical composition for anti-inflammation and antiallergic according to an embodiment of the present invention comprises 1 to 30 parts by weight of a gold scab, 1 to 30 parts by weight of brewer's yeast, 1 to 30 parts by weight of scarlet, 1 to 30 1 to 30 parts by weight of reed, 1 to 20 parts by weight of green tea, 1 to 20 parts by weight of cherry wood, 1 to 20 parts by weight of oak tree and 1 to 10 parts by weight of pine powder are dried, Is prepared by drying each medicament, then pulverizing and mixing, but is not limited thereto.

The method may further include adding 1 to 50 parts by weight of honey to the mixed medicament and mixing the mixture.

When the pharmaceutical composition is prepared in the form of granules or pills, the content of honey is preferably 1 part by weight to 50 parts by weight within 100 parts by weight of the total amount of the pharmaceutical composition, and when the amount of honey is less than 1 part by weight, It is difficult to form a red body, and when the amount exceeds 50 parts by weight, the viscosity is greatly increased, which makes it difficult to dry and the finished products are difficult to maintain their shape due to sticking together.

Honey can be added for the dough to make the ring. In addition, through the addition of honey, the anti-inflammatory and antiallergic potency of the present invention can be increased.

In addition, the pharmaceutical composition may comprise at least one of a pharmaceutically acceptable carrier, excipient, and diluent.

Then, the mixed medicinal material is aged at a temperature of 40 to 65 DEG C for 4 to 10 hours.

When the aging temperature of the mixed medicinal material is 40 캜 or below, there is a problem that it is difficult to form a pharmaceutical composition. When the aging temperature exceeds 65 캜, the viscosity of the medicament increases greatly and drying is difficult.

In addition, if the aging time of the mixed medicament is less than 4 hours, there is a problem in the content of the secondary metabolites, and if it exceeds 10 hours, there is a problem in stability.

Then, a step of formulating the aged medicament into a ring shape with a size of 3 mm to 5 mm is carried out.

Finally, the step of drying the ring is carried out at a temperature of 30 캜 to 45 캜 for 2 hours to 5 hours.

When the drying temperature of the ring is 30 캜 or less, there is a problem that the pharmaceutical composition is difficult to form. When the temperature exceeds 45 캜, the viscosity is greatly increased, which makes drying difficult and the final products stick to each other.

In addition, when the drying time of the ring is less than 2 hours, the ring is broken and there is a problem of the product value and quality. If the drying time exceeds 5 hours, the ring is excessively hardened and cracked.

< Manufacturing example  >

Example

Dried apricots, brewer's yeast, quince trees, grape stems, reeds, green tea, cherry wood, acacia trees and pine mushroom were crushed with a crusher and homogeneously mixed as shown in Table 1 below. In addition, as shown in Table 1 below, honey was added and homogeneously mixed to prepare a mixture.

Thereafter, the resulting mixture was aged at a low temperature of about 4 캜 for 24 hours, and then aged to a size of 3 to 5 mm, and the ring was dried in a hot air dryer at 60 캜 for 18 hours.

Table 1 shows the ingredient contents (unit: parts by weight) of the pharmaceutical composition for anti-inflammation and anti-allergy according to one embodiment of the present invention.

[Table 1]

< Experimental Example  > Example  3 of Anti-allergy  effect

1.1 Cell culture and cytotoxicity measurement

The cytotoxicity of Rat-derived mast cells (RBL-2H3) was assayed by MTT assay. The cell line RBL-2H3 cells were distributed through the Korean Cell Line Bank (Seoul, Korea) and cultured under subculture. The medium used for cell culture was cultured in a 5% CO2 incubator at 37 ° C in MEM medium supplemented with 10% FBS (fetal bovine serum) and 1% antibody (penicillin / streptomycin) And cultured for 2 to 3 days.

3 g of the sample prepared in Example 3 was diluted in 200 ml of sterilized distilled water. After 4 hours, the sample extract filtered with a 47 mm / 1um glass microfiber filter (GE whatman) was activated with IgE and antigen in a ss vacuum filtration apparatus Cells were treated for 12 hours, treated with 5%, 10%, 15%, 20%, 25%, and 30% of the test samples. The cytotoxicity of the samples was measured 24 hours later. The cell viability was increased up to 25% concentration compared to the normal control group, indicating no cytotoxicity.

Therefore, in the test for inhibiting the anti-allergic activity of the subsequent samples, the test substance was treated with concentration conditions (5, 10, and 15%) at which no cytotoxicity was observed to measure the inhibitory effect of the secretion of β-hexosaminidase .

1.2 Mast cell protection effect

Allergic reactions are divided into four types (I-IV), and allergic diseases such as atopic dermatitis, allergic rhinitis and bronchial asthma belong to Type I allergic reaction. Mast cells play an important role in this Type I allergic reaction and are widely distributed in the connective tissues in vivo such as skin, respiratory system, blood vessels and brain. When these mast cells are activated optically or non-physiologically, degranulation is induced, histamine stored in the intracellular granules is liberated, and allergic symptoms appear.

The inhibitory activity of β-hexosaminidase, which is widely used as an indicator of degranulation, was determined by measuring the activity of degranulation inhibition in RBL-2H3 cells.

1.3 Measurement of inhibition of β-Hexosaminidase release

Cells were counted to 5 Х 105 cells / ml using MEM medium (Sigma) containing 10% bovine serum and 1% antibiotics, and then cultured in RPMI 1640 medium supplemented with 1% Mg / ml IgE antibody was added to each well of a 24-well culture plate and cultured in a CO 2 incubator at 37 ° C for 24 hours. After culturing, the culture medium was removed and washed twice with 1 ml of PBS (phosphate buffered saline). Then, 260 μl of the releasing buffer and the sample were added to each concentration, followed by incubation for 10 minutes under the same conditions.

BSA (Bovine Serum Albumin) was added thereto and incubated for 1 hour under the same conditions. After incubation, 200 μL of each solution was centrifuged at 300 rpm for 5 minutes. 50 μL of the supernatant was transferred to a 96-well culture plate, and 50 μL of the substrate was added. The reaction was carried out for 30 minutes under the same conditions. Then, 150 μL of 100 mM carbonate buffer The resultant value was measured at 405 nm on a microplate counter, and the results are shown in Table 2.

Ketotifen fumarate was used as a control in the antiallergic experiment, and ketotifen fumarate was used as an antihistamine.

Table 2 shows the results of the cytotoxic effect of the samples treated with the pharmaceutical composition for anti-inflammation and anti-allergy according to Example 3 of the present invention.

[Table 2]

As shown in Table 2, the cytotoxicity of the sample was measured 24 h after treatment with the concentrations (5%, 10%, 15%, 20%, 25%, 30% The survival rate was increased compared to the normal control group, indicating no cytotoxicity.

The test substances treated with the concentration conditions (5, 10 and 15%) showed 45.72%, 75.32% and 81.47% inhibition effect of β-hexosaminidase, which is liberated from the cells, , And the anti-allergic effect is superior to that of the control group.

Table 3 is a table showing the results of measuring β-Hexosaminidase release inhibitory effect of the sample treated with the pharmaceutical composition for anti-inflammation and anti-allergy according to Example 3 of the present invention.

[Table 3]

While the invention has been shown and described with reference to certain preferred embodiments thereof, it will be understood by those of ordinary skill in the art that various changes in form and details may be made therein without departing from the spirit and scope of the invention as defined by the appended claims. This is possible.

Therefore, the scope of the present invention should not be limited to the described embodiments, but should be determined by the equivalents of the claims, as well as the claims.

Claims (7)

1 to 30 parts by weight of a gold skein, 1 to 30 parts by weight of brewer's yeast, 1 to 30 parts by weight of a quince tree, 1 to 30 parts by weight of a grape stem, 1 to 30 parts by weight of a reed, 1 to 20 parts by weight of a green tea, 20 to 20 parts by weight of an acacia tree, 1 to 20 parts by weight of an acacia tree, and 1 to 10 parts by weight of a pine powder.
The method according to claim 1,
Wherein the pharmaceutical composition further comprises 1 to 50 parts by weight of honey.
The method according to claim 1,
Wherein said pharmaceutical composition comprises at least one of a pharmaceutically acceptable carrier, excipient and diluent.
The method according to claim 1,
Wherein said pharmaceutical composition inhibits the secretion of? -Hexosaminidase.
1 to 30 parts by weight of a gold skein, 1 to 30 parts by weight of brewer's yeast, 1 to 30 parts by weight of a quince tree, 1 to 30 parts by weight of a grape stem, 1 to 30 parts by weight of a reed, 1 to 20 parts by weight of a green tea, 20 to 20 parts by weight of an acacia tree, 1 to 20 parts by weight of an acacia tree, and 1 to 10 parts by weight of a pine source powder, followed by pulverization and mixing;
Aging the mixed medicament at a temperature of 40 캜 to 65 캜 for 4 hours to 10 hours;
Formulating the aged medicament into a ring form having a size of 3 mm to 5 mm; And
Drying the ring at a temperature of 30 ° C to 45 ° C for 2 hours to 5 hours
Or a pharmaceutically acceptable salt or solvate thereof.
6. The method of claim 5,
And adding 1 to 50 parts by weight of honey to the mixed medicament and mixing the mixture.
6. The method of claim 5,
Wherein the pharmaceutical composition comprises at least one of a pharmaceutically acceptable carrier, excipient and diluent.